HEALTHCARE group Stirling
Products has terminated its interest
in acquiring Halcion’s pathology
subsidiary, telling investors that the
move follows proposed changes in
the deal’s structure by Halcion
owners Global Trading Strategies.
Stirling said as a consequence it
was now finalising other funding
arrangements, with a US$10m
capital raising for its TeleMedCare
interests currently “attracting a high
level of interest in New York”.
In response to an ASX query
about its ongoing funding, Stirling
said it expects to announce further
details offinancing within 14 days,
with cash flow expected to increase
significantly as its pharmaceutical
plant in Cape Breton, Canada
commences operation in the
coming months.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Nov 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Nov 10
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.